Sep 9, 2021
The recent US Food and Drug Administration (FDA) approval of anifrolumab for the treatment of systemic lupus erythematosus (SLE) came a decade after the approval of human monoclonal antibody belimumab.
In this episode of the Rheumatology Advisor podcast, we speak with Mary K. Crow, MD, who provides a deeper insight into the evolution of lupus treatments over the years, with a focus on history, barriers in research, information regarding the anifrolumab approval, and the future of drug development in SLE.
We also present the perspectives of a patient with lupus; Christele Felix serves as a Patient Advocate for Lupus Studies (PAL) for the Lupus Research Alliance, provides peer support for those interested in learning about clinical trials in lupus, and has presented on various topics, including health disparities, at the American College of Rheumatology (ACR) annual conference.